Lilly to let 115 workers go in new outsourcing deal
Deal with unit of Massachusetts-based Thermo Fisher Scientific would keep many of the employees working in same
location.
Deal with unit of Massachusetts-based Thermo Fisher Scientific would keep many of the employees working in same
location.
Eli Lilly is interested in assets that may be offered for sale as a result of Sanofi-Aventis SA and Merck & Co.’s plan to
combine their veterinary units.
Sweeping changes phase in slowly for most, but insurers, hospitals, drug companies, employers, workers, medical device makers
and more will eventually feel impact.
Drugmakers and insurers could gain millions of customers under the legislation, but the industry also will pay new fees and
face stricter rules that may shrink profit and fuel mergers.
To pay for the changes, the legislation includes more than $400 billion in higher taxes over a decade, roughly half of it
from a new Medicare payroll tax on individuals with incomes over $200,000 and couples over $250,000.
Netherlands-based Synthon Pharmaceuticals is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine.
Companion Diagnostics Inc. moves from Connecticut to the IU Emerging Technologies Center, hopes to create 30 high-paying jobs
by 2014.
Pharmaceuticals stolen Sunday morning could be worth up to $75 million.
Indianapolis-based Lilly will pay Acrux of West Melbourne, Australia, a $50 million license fee, plus $3 million when manufacturing
assets are transferred, but the deal could be worth millions more.
Indianapolis-based PolicyStat LLC raised $1.15 million in angel capital from 31 individuals and Halo Capital Group.
WellPoint Inc.’s Anthem Blue Cross & Blue Shield of Connecticut may constrain competition through contracts that require
that the insurer receives hospital discounts at least as favorable as any provided to a competitor.
The acquisition will benefit Elanco, Lilly’s animal health division in Greenfield, which has become increasingly important
to Lilly as it braces for patent-protection losses.
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
Drug developer Transition Therapeutics Inc. said Wednesday that it will pay $1 million to license a group of potential diabetes
drugs from Eli Lilly and Co.
While insurers get the blame for rising health-care costs for consumers, surging fees from hospitals and the growing dominance
of such providers may be just as responsible for driving up expenses, according to a new study examining California's
market.
The pharmacy benefits manager, which has major operations in Whitestown, said fourth quarter profit rose 24 percent.
Three major U.S. drugmakers said they have formed a not-for-profit company in Asia to focus on cancer research and treatments.
California’s insurance regulator said Monday his office has found more than 700 violations by the state’s largest for-profit
health insurer, a subsidiary of Indianapolis-based WellPoint.
Insurers WellPoint Inc. and others would get a delay in taxes on premiums and high-cost medical benefits, along with additional
funding for expanding Medicaid, under a White House proposal
Evista generated $1.03 billion in sales last year, of which $348.1 million came outside the United States.